IP Verse

Formulation Of Boronic Acid Compounds - EP3078667

The patent EP3078667 was granted to The United States OF America on Nov 21, 2018. The application was originally filed on Jan 25, 2002 under application number EP16157001A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3078667

THE UNITED STATES OF AMERICA
Application Number
EP16157001A
Filing Date
Jan 25, 2002
Status
Granted And Under Opposition
Oct 19, 2018
Grant Date
Nov 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKAug 21, 2019ELKINGTON AND FIFEADMISSIBLE
ACCORD HEALTHCAREAug 20, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
DR REDDYS LABORATORIES BETAPHARM ARZNEIMITTELAug 20, 2019HOPFNERADMISSIBLE
ZENTIVA KSAug 20, 2019BIRD & BIRDADMISSIBLE
KRKAAug 20, 2019KUTZENBERGER WOLFF & PARTNERWITHDRAWN
PENTAFARMAAug 19, 2019KUTZENBERGER WOLFF & PARTNERADMISSIBLE
SYNTHONAug 16, 2019-ADMISSIBLE
LEK PHARMACEUTICALS DDAug 14, 2019KRAUS & LEDERER PARTGMBBWITHDRAWN
PFIZERAug 7, 2019ELKINGTON AND FIFEADMISSIBLE
FRESENIUS KABI DEUTSCHLANDJun 17, 2019FRESENIUS KABI DEUTSCHLANDADMISSIBLE
TEVA PHARMACEUTICALSMay 29, 2019GRAF VON STOSCH PATENTANWALTSGESELLSCHAFTADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4499082
DESCRIPTIONUS5106948
DESCRIPTIONUS5169841
DESCRIPTIONUS5187157
DESCRIPTIONUS5242904
DESCRIPTIONUS5250720
DESCRIPTIONUS5780454
DESCRIPTIONUS6066730
DESCRIPTIONUS6083903
DESCRIPTIONUS6297217
DESCRIPTIONWO9835691
DESCRIPTIONWO9915183
OPPOSITIONEP0308238
OPPOSITIONEP1355910
OPPOSITIONEP2251344
OPPOSITIONEP3078667
OPPOSITIONUS4360694
OPPOSITIONUS4670262
OPPOSITIONUS5505953
OPPOSITIONUS5536735
OPPOSITIONUS5780454
OPPOSITIONUS5935994
OPPOSITIONUS5962049
OPPOSITIONUS5985842
OPPOSITIONUS6066730
OPPOSITIONUS6083903
OPPOSITIONWO0057887
OPPOSITIONWO02059130
OPPOSITIONWO9613266
OTHEREP1355910
OTHEREP2251344
SEARCHWO9613266

Non-Patent Literature (NPL) Citations (229) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- KORCEK ET AL., J. CHEM. SOC., PERKIN TRANS., (1972), vol. 2, page 242-
DESCRIPTION- SNYDER ET AL., J. AM. CHEM. SOC., (1958), page 3611-
DESCRIPTION- SNYDER ET AL., J M. CHEM. SOC., (1958), page 3611-
OPPOSITION- ADAMS et al., "Proteasome inhibitors: A novel class of potent and effective antitumor agents", A Novel Class of Potent and, vol. 59, no. 11, pages 2615 - 2622, XP002168152-
OPPOSITION- ADAMS et al., "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Agents", Cancer Research, (19990000), vol. 59, no. 11, pages 2615 - 2622, XP002168152-
OPPOSITION- ADAMS et al., "Proteasome Inhibitors: A Novel Class of Potent and Effective Antitumor Aqents", Cancer Research, (19990000), pages 2615 - 2622, XP002168152-
OPPOSITION- ADAMS, J. et al., "Proteasome inhibitors: A novel class of potent and effective antitumor agents", J. Cancer Research, (19990000), vol. 59, pages 2615 - 2627, XP002168152-
OPPOSITION- AGHAJANIAN, C. et al., "A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies", Clin. Cancer Res., (20020000), vol. 8, pages 2505 - 2511, XP055623934-
OPPOSITION- AGHAJANIAN et al., "A Phase I Trial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies", Clinical Cancer Research, (20020800), pages 1 - 8, XP055623934-
OPPOSITION- AGHAJANIAN et al., "A Phase ITrial of the Novel Proteasome Inhibitor PS341 in Advanced Solid Tumor Malignancies", Clinical Cancer Research, (20020800), pages 1 - 8, XP055623934-
OPPOSITION- Ainley Wade Et Al, "Handbook of Pharmaceutical Excipients", Handbook of Pharmaceutical Excipients, (19940000), pages 294 - 298, XP055336531-
OPPOSITION- Ainley Wade Et Al, "Handbook of Pharmaceutical Excipients", Mannitol, (19940000), pages 294 - 298, XP055336204-
OPPOSITION- Allen Scott, "The Velcade story - viewed as a model for how to develop cancer efficiently, millennium`s life-saving Velcade drug", THE BOSTON GLOBE, (06052007), pages 1 - 3, XP055636700-
OPPOSITION- Anonymous, "Bisphosphonates", Drug facts and comparisons, (19990000), page 694, XP055636764-
OPPOSITION- Anonymous, "Chapter 5 : Allgemeine verfahren, Grundoperationen", Pharmazeutische Technologie, (19910000), pages 126 - 129, XP055637966-
OPPOSITION- Anonymous, "Common solvents used in organic chemistry: Table of properties", Division of Organic Chemistry, (10042019), pages 1 - 2, XP055623887-
OPPOSITION- Anonymous, "Guidelines for Authors", The Journal of Organic Chemistry, (20170100), pages 1 - 33, XP055630193-
OPPOSITION- Anonymous, "NATIONAL CANCER INSTITUTE", Velcade: A New Tool in the Fight against Multiple Mveloma, (01052003), pages 1 - 2, XP055623898-
OPPOSITION- Anonymous, "NMR Study of Equimolar Bortezomib-Mannitol Lyophilizate in DMSO-d6", Lek a Sandoz Company, (20171016), pages 1 - 5, XP055904514-
OPPOSITION- Anonymous, "Official monographs / Mannitol", The United States Pharmacopeia, (19950000), page 929, XP055623977-
OPPOSITION- Anonymous, "Official monographs / Mannitol", The United States Pharmacopeia, (19950000), XP055623977-
OPPOSITION- Anonymous, "Overview of Mass Spectrometry", pages 1 - 11-
OPPOSITION- Anonymous, "Physicians' Desk Reference", PDR 54 EDITION 2000, (20000000), pages 1 - 2, XP055636757-
OPPOSITION- anonymous, "Prevacid®", Takeda Pharmaceuticals - Patient information Leaflet, (20090500), pages 1 - 19, XP055630997-
OPPOSITION- Anonymous, "PS-341 in treating patients with advanced solid tumors or lymphoma", Clinical Trials NCT0000402, (20190423), pages 1 - 7, XP055623906-
OPPOSITION- Anonymous, "Report on Reconsti tution and Accelerated Stability Studies", Lek a sandoz company, (20150126), pages 1 - 7, XP055904472-
OPPOSITION- Anonymous, "Report on Stability Studies", Lek a sandoz company, (20161223), pages 1 - 5, XP055904475-
OPPOSITION- Anonymous, "Scientific discussion for the approval of Velcade", EMEA, (20040501), pages 1 - 42, XP055253768-
OPPOSITION- Anonymous, "Search information of PS-341", Clinicaltrials.gov, (20190416), pages 1 - 2, XP055623950-
OPPOSITION- Anonymous, "Summary of Product Characteristics for Velcade®", Velcade®, (20190220), pages 1 - 31, XP055904520-
OPPOSITION- Anonymous, "Summary of Product Characteristics of Velcade", (20190328), pages 1 - 106, XP055624020-
OPPOSITION- Anonymous, "The Journal of Organic Chemistry Guidelines for Authors", JOC, (20170100), pages 1 - 33, XP055904506-
OPPOSITION- anonymous, "Velcade 3.5 mg powder for solutions for injection", Summary of Product Characteristics, (20190220), URL: https://www.medicines.org.uk/emc/product/160/smpc/print, XP055630200-
OPPOSITION- Anonymous, "Velcade (NSC 681239", NATIONAL CANCER INSTITUTE, (01052003), pages 1 - 2, XP055623903-
OPPOSITION- Anonymous, "Velcade (NSC 681239", NATIONAL CANCER INSTITUTE, (20030500), pages 1 - 2, XP055623903-
OPPOSITION- Anonymous, "Velcade (NSC 681239)", NATIONAL CANCER INSTITUTE, pages 1 - 2, XP055623903-
OPPOSITION- Anonymous, "Velcade (NSC 681239)", Velcade: A New Tool in the Fight against Multiple Myeloma, (20030501), pages 1 - 2, URL: https://dtp.cancer.gov/timeline/flash/success_stories/S6_Velcade.htm, XP055623903-
OPPOSITION- AVIS K E, "Parenteral Preparations", Remington's Pharmaceutical Sciences 18TH ED, US, MACK PUBLISHING CO,, (19900000), pages 1565 - 1567, XP000974153-
OPPOSITION- A. WADE et al., "Mannitol", Handbook of Pharmaceutical Excipients, (19940000), pages 294 - 298, XP055336204-
OPPOSITION- BARBER et al., "Fast Atom Bombardment Mass Spectrometry (FAB", J.Chem.Soc., Faraday Trans. I, (19820000), vol. 78, pages 1291 - 1296, XP055630141-
OPPOSITION- BARBER, M. et al., "Fast Atom Bombardment Mass Spectrometry (FAB)", J. Chem. Faraday Trans., (19820000), vol. 1, no. 78, pages 1291 - 1296, XP055630141-
OPPOSITION- BARBER M. et al., "Fast Atom Bombardment Mass Spectrometry (FAB)", J. Chem. Soc. , Faraday Trans. I, (19820000), vol. 78, pages 1291 - 1296, XP055630141-
OPPOSITION- Barnhart E., "Physicians' Desk Reference", PDR 45 EDITION 1991, (19910320), pages 1585 - 1587, XP055636779-
OPPOSITION- Bauer Et Al K H, "PHARMAZEUTISCHE TECHNOLOGIE", Kapitel 5 - Allgemeine Verfarhen, Grundoperationen, (19910000), pages 126 - 129, XP055335903-
OPPOSITION- BAUER, K.H. et al., "Kapitel 5 Allgemeine Verfahren, Grundoperationen", Pharmazeutische Technologie, (19910000), pages 126 - 129, XP055624053-
OPPOSITION- BAUER, K.H. et al., "Kapitel 5 - Allgemeine Verfarhen, Grundoperationen", Pharmazeutische Technologie, Stuttgart, (19910000), pages 126 - 129, XP055335903-
OPPOSITION- BAUER, K.H. et al., "Kaptiel 5 Allgemeine Verfahren, Grundoperationen", Pharmazeutische Technologie, (19910000), pages 126 - 129, XP055624053-
OPPOSITION- B. Nuijen Et Al., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agend Aplidine", PDA Journal of Pharmaceutical Science and Technology, (20000000), vol. 54, no. 3, pages 193 - 208, XP055338550-
OPPOSITION- CAPPOLA, "Freeze Drying", Protein Formulation and Delivery, (20000000), pages 181 - 182, XP055338605-
OPPOSITION- "Cerubine", anonymous, Physicians' Desk Reference. 45th ed., Edward R. Barnhart, (19910000), pages 2373 - 2374, ISBN 978-0-87489-716-5, XP055630973-
OPPOSITION- "Chapter 3", PRAMANIK, B.N. et al., Applied Electrospray Mass Spectrometry, Marcel Dekker, (20020000), ISBN 978-0-8247-0618-8, XP055630135-
OPPOSITION- "cis-Platin", Kenneth A. Connors et al, Chemical Stability of Pharmaceuticals. A Handbook for Pharmacists. 2nd, JOHN WILEY & SONS, (19860000), page 356, XP055630971-
OPPOSITION- "Common solvents used in organic chemistry: Table of properties", Division of Organic Chemistry, (20190409), pages 1 - 2, XP055623887-
OPPOSITION- "Common solvents used in organic chemistry: Table of properties", Division of Organic Chemistry, (20190410), pages 1 - 2, XP055623887-
OPPOSITION- "Dantronele Sodium", anonymous, AHFS. Drug Information, American Hospital Formulary Service, (19910000), page 757, XP055630972-
OPPOSITION- "Deca-Duboralin", Anonymous, Physicians' Desk Reference. 45th ed, Edward R. Barnhart, (19910000), page 1585; 1587, ISBN 978-0-87489-716-6, XP055630977-
OPPOSITION- "Deoxycoformycin", Michael Allwood et al, The Cytotoxics Handbook. 2n ed., RADCLIFFE MEDICAL PRESS, (19930423), page 290, XP055630984-
OPPOSITION- "Epoprostenol sodium", Mosby's Complete Drug Reference (Physician's GenRx) 7th ed., Mosby, (19970000), page II-780; II-782, ISBN 978-0-8151-7203-1, XP055630986-
OPPOSITION- FDA, "Manitol", SCOGS, (1972), Database accession no. 69-65-8, URL: FDA, XP055630130-
OPPOSITION- "Flagyl I.V.", Anonymous, Physicians' Desk Reference. 40th ed., Edward R. Barnhart, (19860000), page 1670, ISBN 978-0-87489-886-2, XP055630974-
OPPOSITION- "Fludarabine phosphate", anonymous, Mosby's GenRx.The Complete Reference For Generic and Brand Drugs 9th ed., Mosby, (19990000), page II-942, ISBN 978-0-32300-625-5, XP055630979-
OPPOSITION- "Freeze Drying", CAPPOLA, Protein Formulation and Delivery, (20000000), pages 181 - 182, ISBN 978-0-8247-7883-5, XP055338605-
OPPOSITION- "Freeze Drying", PIKAL, M. et al, Encyclopedia of Pharmaceutical Technology, Marcel Dekker, (19940000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- Ganguly A. K., "Characterization of Pharmaceuticals and Natural Products by Electrospray Ionization Mass Spectrometry", Ganguly A. K., PRAMANIK B N; ET AL, Applied Electrospray Mass Spectrometry, (20020000), pages 1 - 10, XP055338563-
OPPOSITION- "Gemcitabine Hydrochloride", Anonymous, Mosby's Complete Drug Reference (Physician's GenRx) 7th ed., Mosby, (19970000), page II-982, ISBN 978-0-8151-7203-1, XP055630989-
OPPOSITION- GENNARA, ALFONSO R. et al., "Parenteral preparations", Pharmaceutical Sciences, (19900000), page 1585,1500,1507, XP055624039-
OPPOSITION- GENNARA, ALFONSO R. et al., "Parenteral preparations", Pharmaceutical Sciences, (19900000), XP055624039-
OPPOSITION- GENNARA, A.R. et al., "Parenteral preparations", Pharmaceutical Sciences, (19900000), page 1585, 1500, 1507, XP055624039-
OPPOSITION- "Hycamtin", Anonymous, Physicians' Desk Reference. 54th ed., Medical Economics Company, (20000000), page 3006, ISBN 978-1-56363-330-0, XP055630991-
OPPOSITION- JENNINGS, "Lyophilisation: Introduction and Basic Principles", Pigment Cell Research, (19990000), pages 29 - 33, XP055632180-
OPPOSITION- JENNINGS, T. A., Lyophilization: Introduction and Basic Principles, (19990000), pages 29 - 33, XP055632180-
OPPOSITION- JENNINGS, T. A., "Product Formulation", Lyophilization: Introduction and Basic Principles, (19990000), pages 29 - 33, XP055248887-
OPPOSITION- JENNINGS, T. A., "Product Formulation", Lyophilization: Introduction and Basic Principles, CRC Pres, (19990000), pages 29 - 33, XP055248887-
OPPOSITION- "Kapitel 1", VOIGL, R., Pharmazeutische Technologic, Deutscher Apotheker Verlag, (20000000), pages 23 - 24, ISBN 978-3-7692-2649-6, XP055630112-
OPPOSITION- "Kapitel 5", BAUER, K.H. et al., Pharmazeulische Technologic, Georg Thieme Verlag, (19910000), pages 126 - 129, ISBN 978-3-13-692503-3, XP055335903-
OPPOSITION- KELLY et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation between Conformation and Activity", J. Am. Chem. Soc., (19930000), pages 12637 - 12638, XP055623987-
OPPOSITION- KELLY et al., "Immunosuppressive Boronic Acid Dipeptides: Correlation between Conformation and Activity", J. Am. Chem. Soc., (19930000), vol. 115, pages 12637 - 12638, XP055623987-
OPPOSITION- KNIVILA, H. G. et al., "Areneboronates from diols and polyols", J. Org. Chem., (19540000), vol. 19, no. 5, pages 780 - 783, XP055904336-
OPPOSITION- K. YOSHINO et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strahlenther. Onkol., (19890000), vol. 165, pages 127 - 129, XP055335941-
OPPOSITION- "List of water-miscible solvents", Division of Organic Chemistry, pages 1 - 4-
OPPOSITION- "List of water-miscible solvents", Division of Organic Chemistry, pages 1 - 4, URL: https://ipfs.io/ipfs/QmXoypizjW3WknFijnKLwHCnL72vedxjQKDDPlmXWo6uco/w...-
OPPOSITION- "Mannitol", Ainley Wade et al, Handbook of Pharmaceutical Excipients, (19940000), pages 294 - 298, ISBN 978-0-85369-305-5, XP055336204-
OPPOSITION- "Mannitol", Ainley Wade Et Al, Handbook of Pharmaceutical Excipients second edition, (19940000), pages 294 - 298, XP055336204-
OPPOSITION- MCNALLY et al., "Freeze-drying", Drugs and the Pharmaceutical Sciences - Protein Formulation and Delivery, (20000000), pages 181 - 182, XP055624041-
OPPOSITION- MCNALLY et al., "Freeze-drying", Drugs and the Pharmaceutical Sciences - Protein Formulation and Delivery, (20000000), vol. 99, pages 181 - 182, XP055624041-
OPPOSITION- MCNALLY et al., "Freeze-drying", Protein formulation and delivery, Drugs and the Pharmaceutical Sciences - Protein Formulation and Delivery, (20000000), vol. 99, pages 181 - 182, XP055624041-
OPPOSITION- MICHAEL ALLWOOD ET AL., "Deoxycoformycin", The Cytotoxics Handbook. 2n ed, (19930423), page 290, XP055630984-
OPPOSITION- M PIKAL, "Freeze Drying", Encyclopedia of Pharmaceutical Technology, (19940000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- NATIONAL CANCER INSTITUTE, "Velcade: A New Tool in the Fight against Multiple Myeloma", (20140620), pages 1 - 5, XP055623898-
OPPOSITION- NIRAJ S. AMIN, "Evaluation of Effect of Excipients, Temperature and Humidity on the Stability of Levothyroxine Sodium", Master Thesis, University of Rhode Island, DigitalCommons@URI, (20000000), pages 1 - 356, URL: https://dimtaleonmions.uri.edu/theses/1152-
OPPOSITION- NUIJEN, B. et al., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine", PDA Journal of Pharmaceutical Science and Technology, (20000000), vol. 54, no. 3, pages 193 - 208, XP055338550-
OPPOSITION- NUIJEN, B. et al., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine", PDA Journal of Pharmaceutical Science and Technology, (20000500), vol. 54, no. 3, pages 193 - 208, XP055338550-
OPPOSITION- NUIJEN et al., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine", PDA Journal of Pharmaceutical Science and Technology, (20000000), vol. 54, no. 3, pages 193 - 208, XP055338550-
OPPOSITION- NUIJEN, "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agend Aplidine", PDA Journal of Pharmaceutical Science and Technoloy, (20000000), vol. 54, no. 3, pages 193 - 208, XP055338550-
OPPOSITION- "Official monographs / Mannitol", The United States Pharmacopeia, (19950000), page 929, XP055623977-
OPPOSITION- "Pamidronate Disodium", anonymous, Drug Facts and Comparisons, Facts & Comparisons, (19990000), page 694, ISBN 978-1-57439-038-4, XP055630980-
OPPOSITION- "Parenteral Preparations", Alfonso R Gennara; Et Al, Parenteral - Pharmaceutical Sciences,, (19900000), pages 1585 - 1587, XP055624039-
OPPOSITION- "Parenteral Preparations, Chapter 4", Remington et al., Remington's Pharmaceutical Sciences, Eighteenth Edition, (19910000), pages 1565 - 1567, XP055248815-
OPPOSITION- "Parenteral Preparations", Gennaro A. R., Remington's Pharmaceutics Sciences. 8th ed., Mack Publishing Company, (1990), page 1500, 1585 1567, XP055335885-
OPPOSITION- "Parenteral Preparations", Remington's Pharmaceutical Sciences, (19900000), pages 1565 - 1567, XP055632164-
OPPOSITION- Physicians' Desk Reference, (19820000), page 1638-
OPPOSITION- PIKAL, M. et al., "- Freeze Drying", Encyclopedia of Pharmaceutical Technology, (19920000), pages 275 - 303, XP055248792-
OPPOSITION- PIKAL, M., "Freeze Drying", Encyclopedia of Pharmaceutical Technology, (19920000), pages 1 - 33, XP055638141-
OPPOSITION- PIKAL, M., "Freeze Drying", Encyclopedia of Pharmaceutical Technology - Freeze Drying, (19920000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- PIKAL, M., "Freeze drying", Encyclopedia of Pharmaceutical Technology, New York, (19920000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- Pikal; M J; James Swarbrick Et Al, "Freeze Drying", Encyclopedia of Pharmaceutical Technology, (19920000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- Poster Velcade (PS-341-
OPPOSITION- PRAMANIK, B.N. et al., "3 Characterization of Pharmaceuticals and Natural Products by Electrospray Ionization Mass Spectrometry", Applied Electrospray Mass Spectrometry, (20020000), ISBN 0-8247-0618-8, XP055338563-
OPPOSITION- "Product Formulation", JENNINGS, T. A., Lyophilization: Introduction and Basic Principles. 1st ed., CRC Press, (19990000), pages 29 - 33, ISBN 978-1-57491-081-0, XP055248887-
OPPOSITION- "PS-341 in treating patients with advanced solid tumors or lymphoma", Clinical Trials.gov NCT0000402, (20190423), XP055623906-
OPPOSITION- R VOIGT, "PHARMAZEUTISCHE TECHNOLOGIE FUER STUDIUM UND BERUF,", Pharmazeutische Technologie, Stuttaart, (20000000), pages 23 - 24, XP055335911-
OPPOSITION- R VOIGT, Pharmazeutische Technologie, Stuttgart, (20000000), pages 23 - 24, XP055248877-
OPPOSITION- R VOIGT, "Technologische Grundoperationen", PHARMAZEUTISCHE TECHNOLOGIE FUER STUDIUM UND BERUF, Stuttgart, (20000000), pages 23 - 24, XP055248877-
OPPOSITION- R VOIGT, "Technologische grundoperationen", Pharmazeutische Technologie, Stuttgart, (20000000), pages 23 - 24, XP055248877-
OPPOSITION- "Scientific discussion for the approval of Velcade", EMEA, (20040000), pages 1 - 42, XP055253768-
OPPOSITION- "Scientific Discussion (for the approval of Velcade)", EMEA 2004, (20040501), pages 1 - 42, XP055253768-
OPPOSITION- "Scientific discussion for the approval of Velcade", EMEA, pages 1 - 42, XP055253768-
OPPOSITION- "Scientific Discussion Velcade", EMEA, (20040000), pages 1 - 42-
OPPOSITION- Scott Allen, "The Velcade story - viewed as a model for how to develop cancer efficiently, millennium`s life-saving Velcade drug", The Boston Globe, (20070506), pages 1 - 3, XP055636700-
OPPOSITION- STELLA et al., "Development of parental formulations of experimental cytotoxic agents. i. Rhizoxin (NSC-332598)", International Journal of Pharmaceutics, (19880000), vol. 43, pages 191 - 199, XP055637991-
OPPOSITION- "Summary of Product Characteristics of Velcade", SMPC Velcade, (20190000), pages 1 - 106, XP055624020-
OPPOSITION- Swarbrick J. et al., "- Freeze Drying", Encyclopedia of Pharmaceutical Technology, Volume 6,, (19940000), vol. 6, pages 275 - 303, XP055248792-
OPPOSITION- T. A. JENNINGS, "Lyophilization: Introduction and Basic Principles", (19990831), pages 29 - 33, XP055632180-
OPPOSITION- TANAKA K. et al., "Cryoprotective Effect of Saccharides on Denaturation of Catalase by Freeze-Drying", Chemical and Pharmaceutical Bulletin, (19910000), vol. 39, no. 5, pages 1091 - 1094, XP055338596-
OPPOSITION- TANAKA K. et al., "Cryoprotective Effect of Saccharides on Denaturation of Catalase by Freeze-Drying", Chemical and Pharmaceutical Bulletin, (19910500), vol. 39, no. 5, pages 1091 - 1094, XP055338596-
OPPOSITION- "Technologische Grundoperationen", Pharmazeutische Technologie für studium und Beruf, (20000000), pages 23 - 24, XP055248877-
OPPOSITION- The Story of Velcade? - A Biotech Love Story, page 46pp-
OPPOSITION- The United States Pharmacopeia, (19950000), page 929-
OPPOSITION- "The Velcade story", The Boston Globe, (20070506), pages 1 - 4, XP055623894-
OPPOSITION- "The Velcade story - viewed as a model for how to develop cancer efficiently, millennium`s life-saving Velcade drug", The Boston Globe, (20070506), XP055636700-
OPPOSITION- "Travase Ointment", Huff, Barbara B, et al, Physicians' Desk Reference. 33th ed., Medical Economics, (19790000), page 883, ISBN 978-0-87489-999-3, XP055630995-
OPPOSITION- "Velcade®: New Tool in the Fight against Multiple Myeloma", NATIONAL CANCER INSTITUTE, (20140630), URL: hzps://www.cancer.gov/research/progress/discovery/velcade, XP055623898-
OPPOSITION- "Velcade (NSC 681239)", National Cancer Institute:, URL: https://dtp.cancer.gov/timeline/flash/success_stories/S6_Velcade.htm, XP055623903-
OPPOSITION- VOIGHT, R., "Technologische Grundoperationen", Pharmaceutische Technologie, (20000000), pages 23 - 24, XP055248877-
OPPOSITION- VOIGT, R., Pharmazeutische Technologie, (20000000), pages 23 - 24, XP055335911-
OPPOSITION- VOIGT, R., "Pharmazeutische Technologie", PHARMAZEUTISCHE TECHNOLOGIE FUER STUDIUM UND BERUF, (20000000), pages 23 - 24, XP055335911-
OPPOSITION- WADE, A. et al., "Mannitol", Handbook of Pharmaceutical Excipients, (19940000), pages 294 - 298, XP055336204-
OPPOSITION- YOSHINO et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strahlenther. Onkol., (19890000), vol. 165, no. 2 / 3, pages 127 - 129, XP055335941-
OPPOSITION- YOSHINO, K. et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strablenther. Onkol., (19890000), vol. 165, no. 2-3, pages 127 - 129, XP055335941-
OPPOSITION- YOSHINO K. et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strahlenther. Onkol., (19890000), vol. 165, no. 2/3, pages 127 - 129, XP055335941-
OPPOSITION- YOSHINO, K. et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strahlenther. Onkol., (19890000), vol. 165, pages 127 - 129, XP055335941-
OPPOSITION- YOSHINO, K. et al., "Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides", Strahlenther. Onkol., (19890100), vol. 165, no. 2-3, pages 127 - 129, XP055335941-
OPPOSITION- SARA WU et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pyz-(CO)- Phe-Leu-B(OH)2", Journal of Pharmaceutical Sciences, vol. 89, no. 6, June 2000, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, pages 758 - 765, XP001197158
OPPOSITION- S. WU et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)2", J ournal of Pharmaceutical Sciences, (20000606), vol. 89, doi:doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, pages 758 - 765, XP001197158
OPPOSITION- WU et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pyz- (CO)-Phe-Leu-B(OH)2", Journal of Pharmaceutical Sciences, (20000000), pages 758 - 765, XP001197158
OPPOSITION- WU et al., "DEGRADATION PATHWAYS OF A PEPTIDE BORONIC ACID DERIVATIVE, 2-PYZ-(CO)-PHE-LEU-B(OH)2", Journal of Pharmaceutical Sciences 2000, (20000606), vol. 89, no. 6, pages 758 - 765, XP001197158
OPPOSITION- WU et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pzy-(CO) -Phe-Leu-B(OH)2", Journal of Pharmaceutical Sciences, (20000000), vol. 89, no. 6, pages 758 - 765, XP001197158
OPPOSITION- WU et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pzy-(CO)-Phe-Leu-B(OH)2", Journal of Pharmaceutical Sciences, (20000000), vol. 89, pages 758 - 765, XP001197158
OPPOSITION- WU S. et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2‐Pyz‐(CO)‐Phe‐Leu‐B(OH)2", Journal of Pharmaceutical Science, (20000000), vol. 89, pages 758 - 765, XP001197158
OPPOSITION- WU, S. et al., "Degradation Pathways of a Peptide Boronic Acid Derivative, 2‐Pyz‐(CO)‐Phe‐Leu‐B(OH)2", J. Pharm. Sci., (20000000), vol. 89, no. 6, ISSN 0022-3549, pages 758 - 765, XP001197158
OPPOSITION- WU, S. et al., "DEGRADATION PATHWAYS OF A PEPTIDE BORONIC ACID DERIVATIVE, 2-PYZ-(CO)-PHE-LEU-B(OH)2", J. Pharm. Sci., (20000601), vol. 89, no. 6, pages 758 - 765, XP001197158
OPPOSITION- WU S; WAUGH W; STELLA V J, "Degradation Pathways of a Peptide Boronic Acid Derivative, 2‐Pyz‐(CO)‐Phe‐Leu‐B(OH)2", Journal of Pharmaceutical Sciences, (20000000), vol. 89, no. 6, pages 758 - 765, XP001197158
OPPOSITION- STELLA et al., "Development of parenteral formulations of experimental cytotoxic agents. I. Rhizoxin (NSC-332598", International Journal of Pharmaceutics, (19880000), vol. 43, doi:10.1016/0378-5173(88)90273-6, pages 191 - 199, XP025524696
OPPOSITION- STELLA et al., "Development of parenteral formulations of experimental cytotoxic agents. I. Rhizoxin (NSC-332598", International Journal of Pharmaceutics, (19880000), vol. 43, doi:doi:10.1016/0378-5173(88)90273-6, pages 191 - 199, XP025524696
OPPOSITION- REYNOLDS et al., "Improving Fast Atom Bombardment Mass Spectra: The Influence of Some Controllable Parameters on Spectral Quality", J Am. Soc. Mass Spectrom., (19900300), vol. 1, no. 2, pages 149 - 157, XP028084942
OPPOSITION- Reynolds J D; Cook K D, "Improving Fast Atom Bombardment Mass Spectra: The Influence of Some Controllable Parameters on Spectral Quality", J Am. Soc. Mass Spectrom., (19900000), vol. 1, no. 2, pages 149 - 157, XP028084942
OPPOSITION- REYNOLDS, J.D. et al., "Improving fast atom bombardment mass spectra: The influence of some controllable parameters on spectral quality", J. Am. Mass. Spectrum, (19900000), vol. 1, pages 149 - 157, XP028084942
OPPOSITION- ZHANG, J. et al., "Complexation of polysaccharide and monosaccharide with thiolate boronic acid capped on silver nanoparticle", Analytical Biochemistry, (20040000), vol. 332, pages 253 - 260, XP003012736
OPPOSITION- ZHANG J; GEDDES C D; LAKOWICZ J R, "Complexation of polysaccharide and monosaccharide with thiolate boronic acid capped on silver nanoparticle", Analytical Biochemistry, (20040000), vol. 332, pages 253 - 260, XP003012736
OPPOSITION- FERRIER, R. J., "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), doi:10.1016/S0065-2318(08)60218-8, pages 31 - 80, XP055335949
OPPOSITION- FERRIER, R. J., "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), doi:doi:10.1016/S0065-2318(08)60218-8, pages 31 - 80, XP055335949
OPPOSITION- FERRIER, R.J., "Carbohydrate boronates", Carbohydrate Boronates, in Advances in Carbohydrate Chemistry and Biochemistry, (19780000), pages 31 - 80, XP055335949
OPPOSITION- R J FERRIER, "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), vol. 35, doi:10.1016/S0065-2318(08)60218-8, pages 31 - 80, XP055335949
OPPOSITION- R. J. FERRIER, "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), vol. 35, doi:10.1016/S0065-2318(08)60218-8, pages 31 - 80, XP055335949
OPPOSITION- Teagarden Dirk L., Et Al., "Practical aspects of lyophilization using non-aqueous co-solvent systems", Eur.J.Pharm.Sci., (20020000), vol. 15, pages 115 - 133, XP055169184
OPPOSITION- PLUSKAL et al., "Highly Accurate Chemical Formula Prediction Tool Utilizing High- Resolution Mass Spectra, MS/MS Fragmentation, Heuristic Rules, and Isotope Pattern Matching", Anal. Chem., (20120000), vol. 84, doi:10.1021/ac3000418, pages 4396 - 4403, XP055492004
OPPOSITION- PLUSKAL et al., "Highly Accurate Chemical Formula Prediction Tool Utilizing High-Resolution Mass Spectra, MS/MS Fragmentation, Heuristic Rules, and Isotope Pattern Matching", Anal. Chem., (20120000), vol. 84, doi:doi:10.1021/ac3000418, pages 4396 - 4403, XP055492004
OPPOSITION- PLUSKAL, T. et al., "Highly Accurate Chemical Formula Prediction Tool Utilizing High-Resolution Mass Spectra, MS/MS Fragmentation, Heuristic Rules, and Isotope Pattern Matching", Analytical Chemistry, (20120000), vol. 84, pages 4396 - 4403, XP055492004
OPPOSITION- SHENVI, "Alpha- Aminoboronic Acid Derivatives: Effective Inhibitors of Aminopeptidases", Biochemist., (19860000), pages 1286 - 1291, XP055623997
OPPOSITION- SHENVI, "Alpha- Aminoboronic Acid Derivatives: Effective Inhibitors of Aminopeptidases", Biochemistry, (19860000), vol. 25, pages 1286 - 1291, XP055623997
OPPOSITION- SHENVI, "Alpha-Aminoboronic Acid Derivatives: Effective Inhibitors of Aminopeptidases", Biochemistry, (19860000), vol. 25, pages 1286 - 1291, XP055623997
OPPOSITION- NEMOTO et al., "Synthesis and Biological Properties of Water-Soluble p- Boronophenylalanine Derivatives. Relationship between Water Solubility, Cytotoxicity, and Cellular Uptake", J. Med. Chem., (19950000), vol. 38, doi:10.1021/jm00010a012, page 1673, XP002294784
OPPOSITION- NEMOTO, H. et al., "Synthesis and biological properties of water-soluble p-boronophenylalanine derivatives: Relationship between water solubility, cytotoxicity, and cellular uptake", J. Med. Chem., (19950000), vol. 38, no. 10, pages 1673 - 1678, XP002294784
OPPOSITION- NEMOTO, H. et al., "Synthesis and biological properties of water-soluble p-boronophenylalanine derivatives: Relationship between water solubility, cytotoxicity, and cellular uptake", Journal of Medicinal Chemistry, (19950000), vol. 38, no. 10, pages 1673 - 1678, XP002294784
OPPOSITION- NEMOTO, S. et al., "Synthesis and biological properties of water-soluble p-boronophenylalanine derivatives: Relationship between water solubility, cytotoxicity, and cellular uptake", J. Med. Chem., (19950000), vol. 38, pages 1673 - 1678, XP002294784
OPPOSITION- H. G. KUIVILA et al., "Areneboronates from Diols and Polyols", J. Org. Chem., (19540000), vol. 19, doi:10.1021/jo01370a013, pages 780 - 783, XP055335924
OPPOSITION- KNIVILA, H., G. et al., "ARENEBORONATES FROM DIOLS AND POLYOLS", J. Org. Chem., (19540500), vol. 19, no. 5, pages 780 - 783, XP055335920
OPPOSITION- WILTAYA-AREEKUL, S. et al., "Freeze-Drying of tert-Butyl Alcohol/Water Cosolvent Systems: Effects of Formulation and Process Variables on Residual Solvents", J. Pharma. Sci., (19980400), vol. 87, no. 4, pages 491 - 495, XP000739682
OPPOSITION- WITTAYA-AREEKUL et al., "FREEZE-DRYING OF TERT-BUTYL ALCOHOL/WATER COSOLVENT SYSTEMS: EFFECTS OF FORMULATION AND PROCESS VARIABLES ON RESIDUAL SOLVENTS", Journal of Pharmaceutical Sciences, (19980000), vol. 87, no. 4, pages 491 - 495, XP000739682
OPPOSITION- WITTAYA-AREEKUL, S. et al., "Freeze-Drying of tert-Butyl Alcohol/Water Cosolvent Systems: Effects of Formulation and Process Variables on Residual Solvents", Journal of Pharmaceutical Sciences, (19980000), vol. 87, no. 4, pages 491 - 495, XP000739682
OPPOSITION- WITTAYA-AREEKUL, S. et al., "Freeze-Drying of tert-Butyl Alcohol/Water Cosolvent Systems: Effects of Formulation and Process Variables on Residual Solvents", J. Pharmaceutical Sciences, (19980000), vol. 87, pages 491 - 495, XP000739682
OPPOSITION- WITTAYA-AREEKUL, S. et al., "Freeze-Drying of tert-Butyl Alcohol/Water Cosolvent Systems: Effects of Formulation and Process Variables on Residual Solvents", J. Pharma. Sci., (19980000), vol. 87, no. 4, doi:doi:10.1021/js9702832, pages 491 - 495, XP000739682
OPPOSITION- A. I. KIM et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", Journal of Pharmaceutical Sciences, (19980808), vol. 87, doi:doi:10.1021/js980001d, pages 931 - 935, XP055248890
OPPOSITION- Alexandra I Kim; Michael J Akers; Steven L Nail, "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", Journal of Pharmaceutical Sciences,, (19980000), vol. 87, no. 8, pages 931 - 935, XP055248890
OPPOSITION- KIM, A. I. et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J. Pharma. Sci., (19980000), vol. 87, no. 8, doi:10.1021/js980001d, ISSN 0022-3549, pages 931 - 935, XP055248890
OPPOSITION- KIM, A. I. et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J. Pharma. ScL, (19980800), vol. 87, no. 8, pages 931 - 935, XP055248890
OPPOSITION- KIM, A.L. et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J. Pharmaceutical Sciences, (19980000), vol. 87, pages 931 - 935, XP055248890
OPPOSITION- KIM et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J. Pharma. Sci., (19980000), vol. 87, no. 8, pages 931 - 935, XP055248890
OPPOSITION- KIM et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J.Pharm.Sc., (19980801), vol. 87, no. 8, doi:10.1021/js980001d, pages 931 - 935, XP055248890
OPPOSITION- KIM et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", J Pharm Sci., (19980800), vol. 87, no. 8, doi:10.1021/js980001d, pages 931 - 935, XP055248890
OPPOSITION- KIM et al., "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrytallizing Cosolute", J Pharm Sci., (19980800), vol. 87, no. 8, doi:10.1021/js980001d, pages 931 - 5, XP055248890
OPPOSITION- JULIAN ADAMS et al., "Proteasome inhibition: a new strategy in cancer treatment", Investigational New Drugs, (20000000), vol. 18, pages 109 - 121, XP001095473
OPPOSITION- KASRAIAN et al., "Thermal analysis of the tertiary butyl alcohol water system and its implication on freeze drying", Pharmaceutical Research, (19950000), vol. 12, no. 4, pages 484 - 490, XP002103016
OPPOSITION- KASRAIAN et al., "The effect of tertiary butyl alcohol on the resistance of the dry product layer during primary drying", Pharmaceutical Research, (19950000), vol. 12, no. 4, pages 491 - 495, XP002103015
OPPOSITION- JULIAN ADAMS et al., "New agents in cancer clinical trials", Oncogene, (20001227), vol. 19, pages 6687 - 6692, XP055636731
OPPOSITION- DLL Y. MORI et al., "Complex formation of p-Boronophenylalanine with some monosaccharides", Pigm. Cell Res. Sup., (19890000), vol. 2, pages 273 - 277, XP009006877
OPPOSITION- MORI et al., "- COMPLEX FORMATION OF P-BORONOPHENYLALANINE WITH SOME MONOSACCHARIDES", Pigment Cell Research, (19890000), vol. 2, no. 4, pages 273 - 277, XP009006877
OPPOSITION- MORI, Y. et al., "Complex formation of p-boronophenylalanine with some monosaccharides.", Pigment Cell Res., (19890000), vol. 2, pages 273 - 277, XP009006877
OPPOSITION- MORI, Y. et al., "Complex Formation of p-Boronophenylalanine With Some Monosaccharides", Pigment Cell Research, (19890000), vol. 2, no. 4, doi:10.1111/j.1600-0749.1989.tb00203.x, ISSN 0893-5785, pages 273 - 277, XP009006877
OPPOSITION- MORI, Y. et al., "COMPLEX FORMATION OF P-BORONOPHENYLALANINE WITH SOME MONOSACCHARIDES", Pigment Cell Research, (19890100), vol. 2, no. 4, pages 273 - 277, XP009006877
OPPOSITION- Y MORI et al., "COMPLEX FORMATION OF P-BORONOPHENYLALANINE WITH SOME MONOSACCHARIDES", Pigm. Cell Res. Sup., (19890000), vol. 2, no. 4, pages 273 - 277, XP009006877
OPPOSITION- Y MORI et al., "COMPLEX FORMATION OF P-BORONOPHENYLALANINE WITH SOME MONOSACCHARIDES", Pigm. Cell Res. Sup., (19890000), vol. 2, pages 273 - 277, XP009006877
OPPOSITION- Y MORI et al., "COMPLEX FORMATION OF P-BORONOPHENYLALANINE WITH SOME MONOSACCHARIDES", PIGMENT CELL RESEARCH. SUPPLEMENT, (19890000), vol. 2, no. 04, pages 273 - 277, XP009006877
OPPOSITION- YOSHIHIRO MORI AKIO SUZUKI KAZUO YOSHINO HIDETAKE KAKIHANA, "Complex formation of p-boronophenylalanine with some monosaccharides", Pigment Cell Research, (19890000), vol. 2, no. 4, pages 273 - 277, XP009006877
OPPOSITION- KLASA et al., "Rational Approaches to Design of Therapeutics Targeting Molecular Markers", American Society of Hematoloqy, (20010000), pages 443 - 462, XP055623942
OPPOSITION- KLASA, R.J. et al., "Rational Approaches to Design of Therapeutics Targeting Molecular Markers", Hematology, (20010101), vol. 2001, no. 1, pages 443 - 462, XP055623942
OPPOSITION- ANDRE et al., "Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial", The Annals of Pharmacotherapy, (20050000), vol. 39, doi:10.1345/aph.1E620, pages 1462 - 1466, XP008113077
OPPOSITION- ANDRE et al., "Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial", The Annals of Pharmacotherapy, (20050000), vol. 39, doi:doi:10.1345/aph.1E620, pages 1462 - 1466, XP008113077
OPPOSITION- ANDRE et al., "Stability of BortezOmib 1 -mg/ml Solution in Plastic Syringe and Glass Vial", The Annals of Pharmacotherapy, (20050900), vol. 39, no. 9, pages 1462 - 1466, XP008113077
OPPOSITION- ANDRE et al., "Stability of BortezOmib 1 -mg/mL Solution in Plastic Syringe and Glass Vial", The Annals of Pharmacotherapy, (20050900), vol. 39, no. 9, pages 1462 - 1466, XP008113077
OPPOSITION- ANDRE et al., "Stability of Bortezomib 1-mg/ml Solution in Plastic Syringe and Glass Vial", The Annals of Pharmacotherapy, (20050900), vol. 39, XP008113077
OPPOSITION- ANDRÉ, P. et al., "Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial", The Annals Pharmacotherapy, (20050000), vol. 39, doi:10.1345/aph.1E620, pages 1462 - 1466, XP008113077
OPPOSITION- WALKER et al., "Stability of Bortezomib Reconstituted with 0.9 % Sodium Chloride at 4 °C and Room Temperature (23 °C", Can.J.Hosp.Pharm., (20080000), vol. 61, no. 1, pages 14 - 20, XP008113111
OPPOSITION- WALKER et al., "Stability of Bortezomib Reconstituted with 0,9% Sodium Chloride at 4°C and Room Temperature (23°C", CJHP, (20080000), vol. 61, no. 1, pages 14 - 20, XP008113111
OPPOSITION- WALKER et al., "Stability of Bortezomib Reconstituted with 0,9% Sodium Chloride at 4 °C and Room Temperature (23°C", CJHP, (20080000), vol. 61, no. 1, pages 14 - 20, XP008113111
OPPOSITION- WALKER, S.E. et al., "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4[deg.]C and room temperature (23°C)", CANADIAN SOCIETY OF HOSPITAL PHARMACY, (20080000), vol. 61, pages 14 - 20, XP008113111
OPPOSITION- Walker S E; Milliken D; Law S, "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C)", Can. J. Hosp. Pharm., (20080000), vol. 61, no. 1, pages 14 - 20, XP008113111
OPPOSITION- WALKER, S. et al., "- Stability of bortezomib reconstituted with 0.9% sodium chloride at 4[deg.]C and room temperature (23[deg.]C)", Can. J. Hosp. Pharm., (20080000), vol. 61, no. 1, pages 14 - 20, XP008113111
OPPOSITION- TAKAYAMA, M., "Fast Atom Bombardment Mass Spectrometry: Matrix Effects on Ion Formation and Fragmentation", J. Mass Spectrom. Jpn, (19940000), vol. 42, pages 249 - 275, XP001019771
OPPOSITION- TAKAYAMA, M., "Fast Atom Bombardment Mass Spectrometry: Matrix Effects on Ion Formation and Fragmentation", J. Mass Spectrom. Soc. Jpn., (19940000), vol. 42, no. 5, doi:10.5702/massspec.42.249, pages 249 - 275, XP001019771
OPPOSITION- TAKAYAMA, M., "Fast Atom Bombardment Mass Spectrometry: Matrix Effects on Ion Formation and Fragmentation", J. Mass Spectrom. Soc. Jpn., (19940000), vol. 42, no. 5, pages 249 - 275, XP001019771
OPPOSITION- AJ REDDI, "Why Is Saline So Acidic (and Does It Really Matter?", International Journal of Medical Sciences, (20130000), vol. 10, no. 6, doi:10.7150/ijms.5868, pages 747 - 750, XP055319041
OTHER- "Scientific discussion for the approval of Velcade", EMEA, (20040000), pages 1 - 42, URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000539/WC500048467.pdf, XP055253768-
OTHER- M.M. REICHVILSER et al., "Boronic acid mono- and diesters of aldopentoses", CarbohydrateResearch, (20100226), vol. 345, no. 4, pages 498 - 502, XP026883631
OTHER- R.J. FERRIER, "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), vol. 35, pages 31 - 80, XP055335949
OTHER- D. L, TEAGARDEN et al., "Practical aspects of lyophilization using non-aqueous co-solvent systems", Eur. J. Pharm. Sci., (20020300), vol. 15, no. 2, pages 115 - 133, XP055030590
OTHER- S. WITTAYA-AREEKUL; S.L. NAIL, "Freeze-Drying of tert-Butyl Alcohol/Water Cosolvent Systems: Effects of Formulation and Process Variables on Residual Solvents", Journal of Pharmaceutical Sciences, (19980000), vol. 87, no. 4, pages 491 - 495, XP000739682
SEARCH- WU S ET AL, "DEGRADATION PATHWAYS OF A PEPTIDE BORONIC ACID DERIVATIVE, 2-PYZ-(CO)-PHE-LEU-B(OH)2", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (20000601), vol. 89, no. 6, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, ISSN 0022-3549, pages 758 - 765, XP001197158 [Y] 1-15 * page 759; figure 1 * * page 762 - page 764 *
SEARCH- ALEXANDRA I. KIM ET AL, "The Physical State of Mannitol after Freeze-Drying: Effects of Mannitol Concentration, Freezing Rate, and a Noncrystallizing Cosolute", JOURNAL OF PHARMACEUTICAL SCIENCES, WASHINGTON, US, (19980801), vol. 87, no. 8, doi:10.1021/js980001d, ISSN 0022-3549, pages 931 - 935, XP055248890 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents